返回 Agenda
Session 4B: Medical Errors Due to Product Design and Development
Session Chair(s)
Diana Van Riet-Nales, PharmD, PhD
Senior Assessor; Member of EMA Quality Working Party, Medicines Evaluation Board (MEB), Netherlands
Medication errors may result in patient harm or death. Risk is known to increase when the product design is insufficiently tailored to patient needs e.g. children, (older) patients. Demographic changes strengthen the importance to identify and mitigate risk in science, regulation and drug development.
Speaker(s)
Medication Safety in the Hospital – Challenges and Hurdles
Martin Hug, PhD
Professor, Chief Pharmacist, University Medical Center Freiburg, Germany
Considering the Human Factor When Mitigating Risks of Medication Errors - an Industry Perspective
Isabel Menz, MSc
Managing Director Germany, Medical Human Factors GmbH, Germany
Medication Errors: How the Drug Design May Mitigate Risk - a Regulatory Perspective
Diana Van Riet-Nales, PharmD, PhD
Senior Assessor; Member of EMA Quality Working Party, Medicines Evaluation Board (MEB), Netherlands
Panel Discussion
Sven Stegemann, PhD
Professor of Patient Centric Drug Design and Manufacturing , Graz University of Technology; Capsugel, Austria